Q-omics provides the consensus-scored PSD profile across patient tissues and cancer cell-line models. PSD expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PSD is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, PSD RNA expression shows 19,810 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, BLCA, and GBM as cancer lineages where PSD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSD survival associations across molecular data types. PSD RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSD RNA expression–survival associations across cancer types. High PSD expression shows unfavorable associations in ACC, BLCA and MESO, but favorable associations in LGG, HNSC and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PSD RNA expression.
This table summarizes PSD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PSD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSD shows lower tumor expression in BLCA, COAD, UCEC and STAD and higher tumor expression in LIHC and HNSC. The BLCA box plot shows higher PSD RNA expression in normal versus tumor tissue (log2 FC = −5.122, t-test p < 0.001).
This table shows molecular features associated with PSD in patient tissues and cancer cell lines. In patient samples, PSD shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PSD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
